For the study, researchers from New York City-based Mount Sinai Hospital tested the “in situ vaccination” on 11 patients with advanced-stage lymphoma. The vaccine, injected directly into a tumor, contains immune stimulants that instruct the immune system to destroy the tumor and other cancerous cells in the body.
Researchers found some patients entered full remission for months to years after receiving the treatment. They are also testing the vaccine in breast cancer and head and neck cancer patients through a clinical trial that started in March.
“The in situ vaccine approach has broad implications for multiple types of cancer,” lead author Joshua Brody, MD, director of the lymphoma immunotherapy program at Mount Sinai’s Icahn School of Medicine, said in a press release. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
More articles on clinical leadership & infection control:
New Jersey nurse staffing improved after public disclosure law enacted, study finds
CDC’s secrecy of drug-resistant outbreaks in hospitals sparks patient safety debate
78 measles cases reported in 1 week, says CDC
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.